Clinical Trials Logo

Advanced Gastric Cancer clinical trials

View clinical trials related to Advanced Gastric Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04195828 Active, not recruiting - Clinical trials for Advanced Gastric Cancer

Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Start date: June 18, 2020
Phase: Phase 2
Study type: Interventional

To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate, nab-paclitaxel and S-1

NCT ID: NCT03579784 Active, not recruiting - Clinical trials for Advanced Gastric Cancer

Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer

Start date: November 26, 2018
Phase: Phase 2
Study type: Interventional

<Research Hypothesis> The dynamics of immune systems by Olaparib and its changes by combination with immune-oncology agents will be uncovered. The combination of Olaparib with Durvalumab with paclitaxel is tolerable and efficacious in gastric cancer. <Objectives> Primary Objectives: To assess the effect of Durvalumab in combination with olaparib and paclitaxel on DCR (Disease control rate) in gastric cancer patients -Disease control rate (based on RECIST v1.1) Secondary Objective(s): - Efficacy: overall response rate (RECIST 1.1, ir response), progression-free survival, duration of response, overall survival, overall survival at 6 month, overall survival at 1 year, EORTC QLQ-C30, - Safety: toxicity (CTCAE V4.1), irAE

NCT ID: NCT03223376 Active, not recruiting - Clinical trials for Advanced Gastric Cancer

A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)

FRUTIGA
Start date: October 18, 2017
Phase: Phase 3
Study type: Interventional

Fruquintinib once daily in 4 weeks treatment cycle (three weeks on and one week off) in combination with Paclitaxel 80mg/㎡(day1, 8, 15 of 4 weeks cycle) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with advanced GC in ph1b/2 study. This study is aimed to evaluate the efficacy and safety of Fruquintinib in combination with Paclitaxel in the treatment of patients with aGC who have progressed after first line standard chemotherapy.